Pharmacogenetics‐Based New Therapeutic Concepts

References

• Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469–497, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bönicke R., Losboa B. P. Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen (Untersuchungen an eineiigen Zwillingen). Naturwissenschaften 1957; 44: 314
   Web of Science ®Google Scholar
• Brockmöller J., Kirchheiner J., Meisel C., Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1: 125–151, [CSA]
   PubMedGoogle Scholar
• Brockmöller J., Kirchheiner J., Schmider J., Walter S., Sachse C., Müller‐Oerlinghausen B., Roots I. The impact on the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 2002; 72: 438–452, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cole S. P.C., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Steward A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug‐resistant human lung cancer cell line. Science 1992; 258: 1650–1654, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cooke G. E., Bray P. F., Hamlington J. D., Pham D. M., Goldschmidt‐Clermont P. J. PlA2 polymorphism and efficacy of aspirin [letter]. Lancet 1998; 351: 1253, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cordon‐Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P‐glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990; 38: 1277–1287
   PubMed Web of Science ®Google Scholar
• Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Rivera R., Stella P., Troffa C., Zagato L., Bianchi G. Polymorphisms of alpha‐adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353–1357, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cvetkovic M., Leake B., Fromm M. F., Wilkinson G. R., Kim R. B. OATP and P‐glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999; 27: 866–871, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dishy V., Sofowora G. G., Xie H. G., Kim R. B., Byrne D. W., Stein C. M., Wood A. J. The effect of common polymorphisms of the beta2‐adrenergic receptor on agonist‐mediated vascular desensitization. N. Engl. J. Med. 2001; 345: 1030–1035, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dojo M., Azuma T., Saito T., Ohtani M., Muramatsu A., Kuriyama M. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole and rabeprazole), amoxycillin, and clarithromycin. Digest Liver Dis. 2001; 33: 671–675, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Drazen J. M., Yandava C. N., Dube L., Szczerback N., Hippensteel R., Pillari A., Israel E., Schork N., Silverman E. S., Katz D. A., Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti‐asthma treatment. Nat. Genet. 1999; 22: 168–170, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Drysdale C. M., McGraw D. W., Stack C. B., Stephens J. C., Judson R. S., Nandabalan K., Arnold K., Ruano G., Liggett S. B. Complex promoter and coding region beta 2‐adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 10483–10488, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Esteller M., Garcia‐Foncillas J., Andion E., Goodman S. N., Hidalgo O. F., Vanaclocha V., Baylin S. B., Herman J. G. Inactivation of the DNA‐repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000; 343: 1350–1354, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fellay J., Marzolini C., Meaden E. R., Back D. J., Buclin T., Chave J. P., Decoster L. A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A. H., Vernazza P., Eap C. B., Telenti A., Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV‐1‐infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30–36, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Furuta T., Ohashi K., Kamata T., Tahashima M., Kosuge K., Kawasaki T., Hanai H., Kobuta T., Ishizaki T., Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 1998; 129: 1027–1030, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Furuta T., Shirai N., Takashima M., Xiao F., Hanai H., Sugimura H., Ohashi K., Ishizaki T., Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001; 69: 158–168, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Furuta T., Shirai N., Takashima M., Xiao F., Hanai H., Kazuko N., Sugimura H., Ohashi K., Ishizaki T. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341–348, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Furuta T., Shirai N., Watanabe F., Honda S., Takeuchi K., Iida T., Sato Y., Kajimura M., Futami H., Takayanagi S., Yamada M., Ohashi K., Ishizaki T., Hanai H. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 2002; 72: 453–460, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gerloff T., Schäfer M., Johne A., Oselin K., Meisel C., Cascorbi I., Roots I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 2002; 54: 610–616, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hitzl M., Drescher S., van der Kuip H., Schaffeler E., Fischer J., Schwab M., Eichelbaum M., Fromm M. F. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P‐glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 1–6, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hoffmeyer S., Burk O., von Richter O., Arnold H. P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug‐resistance gene: multiple sequence variations and correlation of one allele with P‐glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 3473–3478, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W. P., Kirchgessner T. G. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver‐specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl‐CoA reductase inhibitor transporters. J. Biol. Chem. 1999; 274: 37161–37168, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Inaba T., Mizuno M., Kawai K., Yokota K., Oguma K., Miyoshi M., Take S., Okada H., Tsuji T. Helicobacter pylori infection: CYP2C19 genotype and serum ferritin. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J. Gastroenterol. Hepatol. 2002; 17: 748–753, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ishizuka H., Kubota T., Hayashi N., Otani Y., Kumai K., Kitajima M. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 1998; 287: 37–42, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Isomoto H., Inoue K., Furusu H., Nishiyama H., Shikuwa S., Omagari K., Mizuta Y., Murase K., Murata I., Kohno S. Lafutidine, a novel histamine H2‐receptor agonist, vs. lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 2003; 8: 111–119, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Israel E., Drazen J. M., Liggett S. B., Boushey H. A., Cherniack R. M., Chinchilli V. M., Cooper D. M., Fahy J. V., Fish J. E., Ford J. G., Kraft M., Kunselman S., Lazarus S. C., Lemanske R. F., Jr., Martin R. J., McLean D. E., Peters S. P., Silverman E. K., Sorkness C. A., Szefler S. J., Weiss S. T., Yandava C. N., National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. The effect of polymorphisms of the beta(2)‐adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 2000; 162: 75–80, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Israel E., Drazen J. M., Liggett S. B., Boushey H. A., Cherniack R. M., Chinchilli V. M., Cooper D. M., Fahy J. V., Fish J. E., Ford J. G., Kraft M., Kunselman S., Lazarus S. C., Lemanske R. F., Jr., Martin R. J., McLean D. E., Peters S. P., Silverman E. K., Sorkness C. A., Szefler S. J., Weiss S. T., Yandava C. N., National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Effect of polymorphism of the beta(2)‐adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 2001; 124: 183–186, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Johne A., Köpke K., Gerloff T., Mai I., Rietbrock S., Meisel C., Hoffmeyer S., Kerb R., Fromm M. F., Brinkmann U., Eichelbaum M., Brockmöller J., Cascorbi I., Roots I. Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 2002; 72: 584–594, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Juranka P. F., Zastawny R. L., Ling U. P‐glycoprotein: multidrug‐resistance and a superfamily of membrane‐associated transport proteins. FASEB J. 1989; 3: 2583–2592, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kaiser R., Sezer O., Papies A., Bauer S., Schelenz C., Tremblay P. B., Possinger K., Roots I., Brockmöller J. Patient‐tailored antiemetic treatment with 5‐hydroxytryptamine type 3 receptor antagonists according to cytochrome P‐450 2D6 genotypes. J. Clin. Oncol. 2002; 20: 2805–2811, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kaiser R., Hofer A., Grapengiesser A., Gasser T., Kupsch A., Roots I., Brockmöller J. L‐Dopa‐induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750–1755, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kaiser R., Tremblay P. B., Sezer O., Possinger K., Roots I., Brockmöller J. Investigation of the association between 5‐HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5‐HT3 receptor antagonists. Pharmacogenetics 2004; 14: 271–278, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956; 2: 576–577, [CROSSREF]
   Google Scholar
• Kirchheiner J., Brøsen K., Dahl M., Gram L., Kasper S., Roots I., Sjöqvist F., Spina E., Brockmöller J. CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages. Acta. Psychiatr. Scand. Suppl. 2001; 104: 173–192, [CROSSREF]
   Google Scholar
• Kirchheiner J., Meisel C., Goldammer M., Gerloff T., Kaiser R., Roots I. Pharmakogenetik als basis neuer therapiekonzepte. Bundesgesundheitsblatt 2003; 46: 835–844, [CROSSREF]
   Google Scholar
• Kirchheiner J., Müller G., Meineke I., Wernecke K. D., Roots I., Brockmöller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J. Clin. Psychopharmacol. 2003; 23: 459–466, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kirchheiner J., Nickchen K., Bauer M., Wong M. L., Licinio J., Roots I., Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004; 9: 442–473, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kruijtzer C. M., Beijnen J. H., Schellens J. H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002; 7: 516–530, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kuivenhoven J. A., Jukema J. W., Zwinderman A. H., de Knijff P., McPherson R., Bruschke A. V., Lie K. I., Kastelein J. J. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 1998; 338: 86–93, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kullak‐Ublick G. A., Ismair M. G., Stieger B., Landmann L., Huber R., Pizzagalli F., Fattinger K., Meier P. J., Hagenbuch B. Organic anion‐transporting polypeptide B (OATP‐B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525–533, [CSA]
   PubMed Web of Science ®Google Scholar
• Lee V. H.L. Membrane transporters. Eur. J. Pharm. Sci. 2000; 11: S41–S50, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liggett S. B. Pharmacogenetic applications of the human genome project. Nat. Med. 2001; 7: 281–283, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lima J. J., Thomason D. B., Mohamed M. H., Eberle L. V., Self T. H., Johnson J. A. Impact of genetic polymorphisms of the beta2‐adrenergic receptor on albuterol bronchodilatator pharmacodynamics. Clin. Pharmacol. Ther. 1999; 65: 519–525, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lutz M., Schwab M., Griese E. U., Marx C., Müller‐Oerlinghausen B., Schönhofer P. S., Meisner C., Gleiter C. H., Eichelbaum M., Mörike K. Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism. Pharmacogenetics 2002; 12: 73–75, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Meier P. J., Eckhardt U., Schroeder A., Hagenbuch B., Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 1997; 26: 1667–1677, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Meisel C., Roots I., Cascorbi I., Brinkmann U., Brockmöller J. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin. Chem. Lab. Med. 2000; 38: 869–876, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Meisel C., Gerloff T., Kirchheiner J., Mrozikiewicz P. M., Niewinski P., Brockmöller J., Roots I. Implications of pharmacogenetics for individualizing drug treatment and for study design. J. Mol. Med. 2003; 81: 154–167, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Michalski C., Cui Y., Nies A. T., Nuessler A. K., Neuhaus P., Zanger U. M., Klein K., Eichelbaum M., Keppler D., Konig J. A naturally occuring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 2002; 277: 43058–43063, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Michelson A. D., Furman M. I., Goldschmidt‐Clermont P., Mascelli M. A., Hendrix C., Coleman L., Hamlington J., Barnard M. R., Kichler T., Christie D. J., Kundu S., Bray P. F. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013–1018, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Miki I., Aoyama N., Sakai T., Shirasaka T., Wambura C. M., Maekawa S., Kuroda K., Tamura T., Kita T., Sakaeda T., Okumura K., Kasuga M. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole‐ or rabeprazole‐based triple therapy in Japan. Eur. J. Gastroenterol. Hepatol. 2003; 15: 27–33, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Miyoshi M., Mizuno M., Ishiki K., Nagahara Y., Maga T., Torigoe T., Nasu J., Okada H., Yokota K., Oguma K., Tsuji T. Therapy for Helicobacter pylori infection and CYP2C19 polymorphism. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J. Gastroenterol. Hepatol. 2001; 16: 723–728, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mwinyi J., Johne A., Bauer S., Roots I., Gerloff T. Evidence for inverse effects of OATP‐C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 2004; 75: 415–421, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Tarane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S., Otsubo K., Sugiyama Y. Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003; 73: 554–565, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nozawa T., Nakajima M., Tamai I., Noda K., Nezu J., Sai Y., Tsuji A., Yokoi T. Genetic polymorphisms of human organic anion transporters OATP‐C (SLC21A6) and OATP‐B (SLC21A9): allelic frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 2002; 302: 804–813, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pang K. S., Wang P. J., Chung A. J., Wolkoff A. W. The modified dipeptide, enalapril, an angiotensin‐converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 1998; 28: 1341–1346, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Paulusma C. C., Oude Elferink R. P. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med. 1997; 75: 420–428, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Poirier J., Delisle M. C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., Gilfix B. M., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 12260–12264, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rao V. V., Dahlheimer J. L., Bardgett M. E., Snyder A. Z., Finch R. A., Sartorelli A. C., Piwnica‐Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance‐associated protein contribute to the blood‐cerebrospinal‐fluid drug‐permeability barrier. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 3900–3905, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Remmer H. Die Beschleunigung des Evipanabbaues unter der Wirkung von Barbituraten. Naturwissenschaften 1958; 45: 189–190, [CROSSREF]
   Web of Science ®Google Scholar
• Remmer H., Alsleben B. Die Aktivierung der Entgiftung in den Lebermikrosomen während der Gewöhnung. Klin. Wschr. 1958; 36: 332–333, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Remmer H., Schoene B., Fleischmann R. A. Induction of the unspecific microsomal hydroxylase in the human liver. Drug Metab. Disposition 1973; 1: 224–230
   PubMed Web of Science ®Google Scholar
• Rost K. L., Roots I. Nonlinear kinetics after high‐dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996; 23: 1491–1497, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian polulation: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 265–271, [CSA]
   PubMedGoogle Scholar
• Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., Morita Y., Tamura T., Aoyama N., Hirai M., Kasuga M., Okumura K. MDR1 genotype‐related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001; 18: 1400–1404, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schoene B., Fleischmann R. A., Remmer H., v. Oldershausen H. F. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur. J. Clin. Pharmacol. 1972; 4: 65–73, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schwab M., Schäffeler E., Treiber G., Klotz U. Eradication of Helicobacter pylori by short term lansoprazole quadruple therapy in Caucasians depends on CYP2C19 genotype. European Collaboration: Towards drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics, Istanbul, June, 24–28, F. C. Tulunay, M. Orme. Springer Verlag, Berlin 2003; 96
   Google Scholar
• Sesti F., Abbott G. W., Wei J., Murray K. T., Saksena S., Schwartz P. J., Priori S. G., Roden D. M., George A. L., Jr., Goldstein S. A. A common polymorphism associated with antibiotic‐induced cardiac arrhythmia. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 10613–10618, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder F., Sperker B., Warzok R., Kroemer H. K., Cascorbi I. The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 2002; 72: 572–583, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Take S., Mizuno M., Ishiki K., Nagahara Y., Yoshida T., Inaba T., Yamamoto K., Okada H., Yokota K., Oguma K., Shiratori Y. Interleukin‐1β genetic polymorphism influences the effect of cytochrome P2C19 genotype on the cure rate of 1‐week triple therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 2003; 98(11)2403–2408, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tamai I., Nezu J., Uchino H., Sai Y., Oku A., Shimane M., Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 2000; 273: 251–260, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tanigawara Y. Role of P‐glycoprotein in drug disposition. Ther. Drug Monit. 2000; 22: 137–140, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tirona R. G., Leake B. F., Merino G., Kim R. B. Polymorphisms in OATP‐C: identification of multiple allelic variants associated with altered transport activity among European‐ and African–Americans. J. Biol. Chem. 2001; 276: 35669–35675, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Treiber G., Schwabe M., Ammon S., Walker S., Klotz U., Malfertheiner P. Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors. Aliment Pharmacol. Ther. 2004; 19(2)219–231, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tremblay P. B., Kaiser R., Sezer O., Rosler N., Schelenz C., Possinger K., Roots I., Brockmöller J. Variations in the 5‐hydroxytryptamine type 3B receptor gene as predictors of the efficacy of entiemetic treatment in cancer patients. J. Clin. Oncol. 2003; 21: 2147–2155, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ueda S., Meredith P. A., Morton J. J., Connell J. M., Elliott H. L. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98: 2148–2153, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vormfelde S. V., Burckhardt G., Zirk A., Wojnowski L., Brockmöller J. Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 2003; 4: 701–734, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wheeler G. L., Braden G. A., Bray P. F., Marciniak S. J., Mascelli M. A., Sane D. C. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am. Heart. J. 2002; 143: 76–82, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar